Coreline Soft KRX:384470KOSDAQ

코어라인소프트 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days2
DART filings, 7 days1
Articles tracked51since Sep 11

In Q2 2026, Coreline Soft reported an operating loss of ₩2.4bn. Coreline Soft (코어라인소프트) appeared in 2 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 19 with 5 articles. The most common catalyst was clinical & approvals (5).

Filing signals 4 quarters of losses Litigation Screener

Coreline Soft quarterly results consolidated, KRW

QuarterOperating profitNet income
Q2 2026−₩2.4bn−₩3.7bn
Q1 2026−₩3.1bn−₩3.2bn
Q4 2025 derived−₩2.9bn−₩3.2bn
Q3 2025−₩3.6bn−₩3.7bn
Q2 2025−₩3.2bn−₩3.6bn
Q1 2025−₩3.7bn−₩4.0bn
Q4 2024 derived−₩3.7bn−₩4.4bn
Q3 2024−₩3.4bn−₩3.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Coreline Soft top stories 2 weeks, by number of outlets

  1. 1
    코어라인소프트, 대동맥 분석 솔루션 美 FDA 허가
    3 outlets · 3 articlesFirst report Oct 19 14:40 핀포인트뉴스Regulatory approval
  2. 2
    코어라인소프트, 폐암 검진 AI ‘검출 넘어 관리까지’…美 학회서 플랫폼 소개
    1 outlets · 1 articlesFirst report Oct 23 23:10 더바이오Negative news
  3. 3
    코어라인소프트, FDA 허가 제품 13개 확보…심혈관 분석으로 확장
    1 outlets · 1 articlesFirst report Oct 19 14:25 한스경제Regulatory approval
  4. 4
    코어라인소프트, ‘AVIEW Aorta Metrics’ 美 FDA 허가…13번째 승인 제품 확보
    1 outlets · 1 articlesFirst report Oct 19 14:35 더바이오Regulatory approval
  5. 5
    코어라인소프트, 'AVIEW LCS' 목 CT 누락 폐암 절반 검출
    1 outlets · 1 articlesFirst report Oct 22 10:38 바이오타임즈Negative news
  6. 6

Latest Coreline Soft news Korean headlines